Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 4/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417138 | 0.83 | KDM5A (0.36) | KDM5AWDR5CPA1CPB2CDK5 | |
| SCHEMBL18199171 | 0.83 | KDM5A (0.33) | KDM5AWDR5 | |
| SCHEMBL16843172 | 0.81 | GCK (0.35) | KDM5ACPA1CPB2CDK5CDK5R1 | |
| SCHEMBL18250318 | 0.80 | KDM5A (0.32) | KDM5A | |
| SCHEMBL27922449 | 0.80 | KDM5A (0.32) | KDM5ACPA1CPB2CDK5CDK5R1 | |
| SCHEMBL18250281 | 0.78 | PSEN1 (0.31) | — | |
| SCHEMBL24936219 | 0.75 | WDR5 (0.36) | WDR5 | |
| SCHEMBL24642790 | 0.74 | CPA1 (0.30) | CPA1CPB2 | |
| SCHEMBL27940982 | 0.74 | CNR2 (0.32) | — | |
| SCHEMBL20122344 | 0.71 | KDM5A (0.37) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5036000-A | Threshold color control system | ENZYMATICS, INC. (US) | 1991-07-30 | — | — | US | claimed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11787766-B2 | Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11739321-B2 | Compositions and methods for genomic DNA and gene expression analysis in single cells | AGILENT TECHNOLOGIES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8729114-B2 | Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| CN-103361630-A | Group 2 imidazolate formulations for direct liquid injection | AIR PROD & CHEM | 2013-10-23 | — | — | CN | disclosed |
| US-20130158018-A1 | Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | KDM5A 228/4885WDR5 757/4885CPA1 3461/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | KDM5A 4071/4885WDR5 2009/4885CPA1 3092/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | KDM5A 4228/4885WDR5 2237/4885CPA1 1901/4885 |
| US-11739321-B2 | Compositions and methods for genomic DNA and gene expression analysis in single cells | TFAM, POLRMT, SSBP1 | KDM5A 2239/4885WDR5 2978/4885CPA1 3372/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | KDM5A 845/4885WDR5 1831/4885CPA1 3753/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | KDM5A 4492/4885WDR5 1588/4885CPA1 3952/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | KDM5A 4021/4885WDR5 765/4885CPA1 3896/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | KDM5A 228/4885WDR5 757/4885CPA1 3461/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | KDM5A 826/4885WDR5 828/4885CPA1 932/4885 |
| US-20130158018-A1 | Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S | CTSS, CTSV, CTSF | KDM5A 4596/4885WDR5 4790/4885CPA1 43/4885 |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | KDM5A 1721/4885WDR5 3720/4885CPA1 4718/4885 |
| US-11787766-B2 | Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof | CD274, PDCD1, PDCD1LG2 | KDM5A 2542/4885WDR5 3347/4885CPA1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.